197 related articles for article (PubMed ID: 7652498)
1. Changing role of carbapenems in the treatment of lower respiratory tract infections.
Lode H; Hamacher J; Eller J; Schaberg T
Scand J Infect Dis Suppl; 1995; 96():17-23. PubMed ID: 7652498
[TBL] [Abstract][Full Text] [Related]
2. Multicenter randomized trial comparing meropenem (1.5 g daily) and imipenem/cilastatin (2 g daily) in the hospital treatment of community-acquired pneumonia.
Bartoloni A; Strohmeyer M; Corti G; Buonomini MI; Franchino L; Romanelli G; Moretti AM; De Vizzi GB; Petraglia A; Mancini P; Atzeni R; Fogliani V; Giura R; Paradisi F
Drugs Exp Clin Res; 1999; 25(6):243-52. PubMed ID: 10713862
[TBL] [Abstract][Full Text] [Related]
3. A randomized, controlled clinical trial on meropenem versus imipenem/cilastatin for the treatment of bacterial infections.
Hou F; Li J; Wu G; Zheng B; Chen Y; Gu J; Wang H; Huo L; Xue X; Jia C; Yin Y; Tian X; Ren S
Chin Med J (Engl); 2002 Dec; 115(12):1849-54. PubMed ID: 12622937
[TBL] [Abstract][Full Text] [Related]
4. Intramuscular meropenem in the treatment of bacterial infections of the urinary and lower respiratory tracts. Italian Intramuscular Meropenem Study Group.
Romanelli G; Cravarezza P
J Antimicrob Chemother; 1995 Jul; 36 Suppl A():109-19. PubMed ID: 8543487
[TBL] [Abstract][Full Text] [Related]
5. Meropenem versus imipenem/cilastatin in the treatment of sepsis in Chinese patients.
Kuo BI; Fung CP; Liu CY
Zhonghua Yi Xue Za Zhi (Taipei); 2000 May; 63(5):361-7. PubMed ID: 10862445
[TBL] [Abstract][Full Text] [Related]
6. The role of carbapenems in the treatment of severe nosocomial respiratory tract infections.
Joseph J; Rodvold KA
Expert Opin Pharmacother; 2008 Mar; 9(4):561-75. PubMed ID: 18312158
[TBL] [Abstract][Full Text] [Related]
7. Prospective, randomised, multicentre study of meropenem versus imipenem/cilastatin as empiric monotherapy in severe nosocomial infections.
Garau J; Blanquer J; Cobo L; Corcia S; Daguerre M; de Latorre FJ; León C; Del Nogal F; Net A; Rello J
Eur J Clin Microbiol Infect Dis; 1997 Nov; 16(11):789-96. PubMed ID: 9447899
[TBL] [Abstract][Full Text] [Related]
8. [A randomized, controlled clinical trial of meropenem and imipenem/cilastatin in the treatment of acute bacterial infections].
Hou F; Wu G; Zheng B
Zhonghua Nei Ke Za Zhi; 2001 Sep; 40(9):589-93. PubMed ID: 11758237
[TBL] [Abstract][Full Text] [Related]
9. Comparison of 30-min and 3-h infusion regimens for imipenem/cilastatin and for meropenem evaluated by Monte Carlo simulation.
Lee LS; Kinzig-Schippers M; Nafziger AN; Ma L; Sörgel F; Jones RN; Drusano GL; Bertino JS
Diagn Microbiol Infect Dis; 2010 Nov; 68(3):251-8. PubMed ID: 20851549
[TBL] [Abstract][Full Text] [Related]
10. Intravenous meropenem versus imipenem/cilastatin in the treatment of serious bacterial infections in hospitalized patients. Meropenem Serious Infection Study Group.
Colardyn F; Faulkner KL
J Antimicrob Chemother; 1996 Sep; 38(3):523-37. PubMed ID: 8889726
[TBL] [Abstract][Full Text] [Related]
11. Meropenem, a new carbapenem antibiotic.
Fish DN; Singletary TJ
Pharmacotherapy; 1997; 17(4):644-69. PubMed ID: 9250544
[TBL] [Abstract][Full Text] [Related]
12. Meropenem versus imipenem/cilastatin in intra-abdominal infections requiring surgery. Meropenem Study Group.
Geroulanos SJ
J Antimicrob Chemother; 1995 Jul; 36 Suppl A():191-205. PubMed ID: 8543495
[TBL] [Abstract][Full Text] [Related]
13. Meropenem versus imipenem/cilastatin in the treatment of hospitalized patients with skin and soft tissue infections.
Nichols RL; Smith JW; Geckler RW; Wilson SE
South Med J; 1995 Apr; 88(4):397-404. PubMed ID: 7716590
[TBL] [Abstract][Full Text] [Related]
14. Meropenem versus imipenem/cilastatin as empirical monotherapy for serious bacterial infections in the intensive care unit.
Verwaest C;
Clin Microbiol Infect; 2000 Jun; 6(6):294-302. PubMed ID: 11168137
[TBL] [Abstract][Full Text] [Related]
15. Update on the efficacy and tolerability of meropenem in the treatment of serious bacterial infections.
Mohr JF
Clin Infect Dis; 2008 Sep; 47 Suppl 1():S41-51. PubMed ID: 18713049
[TBL] [Abstract][Full Text] [Related]
16. Is it safe to use carbapenems in patients with a history of allergy to penicillin?
Sodhi M; Axtell SS; Callahan J; Shekar R
J Antimicrob Chemother; 2004 Dec; 54(6):1155-7. PubMed ID: 15486083
[TBL] [Abstract][Full Text] [Related]
17. Carbapenems: a potent class of antibiotics.
Nicolau DP
Expert Opin Pharmacother; 2008 Jan; 9(1):23-37. PubMed ID: 18076336
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and tolerability of IV doripenem versus meropenem in adults with complicated intra-abdominal infection: a phase III, prospective, multicenter, randomized, double-blind, noninferiority study.
Lucasti C; Jasovich A; Umeh O; Jiang J; Kaniga K; Friedland I
Clin Ther; 2008 May; 30(5):868-83. PubMed ID: 18555934
[TBL] [Abstract][Full Text] [Related]
19. Treatment of obstetric and gynecologic infections with meropenem: comparison with imipenem/cilastatin.
Maggioni P; Di Stefano F; Facchini V; Irato S; Mancuso S; Colombo M; Massobrio M; Melis GB; Crosignani P
J Chemother; 1998 Apr; 10(2):114-21. PubMed ID: 9603636
[TBL] [Abstract][Full Text] [Related]
20. A multicenter, randomized controlled clinical study on biapenem and imipenem/cilastatin injection in the treatment of respiratory and urinary tract infections.
Jia B; Lu P; Huang W; Li C; Huang A; Zhou X; Zhang W; Wu G; Zhang G
Chemotherapy; 2010; 56(4):285-90. PubMed ID: 20714145
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
